EVA Infusion Bag Market Report: Trends, Forecast and Competitive Analysis to 2035

EVA Infusion Bag Market

The future of the global eva infusion bag market looks promising with opportunities in the hospital and clinic markets. The global eva infusion bag market is expected to reach an estimated $526 million by 2035 from $323 million in 2027 with a CAGR of 6.1% from 2027 to 2035. The major drivers for this market are the increasing demand for intravenous drug delivery, the rising need for safer medical packaging solutions, and the growing adoption of disposable medical products.

• Lucintel forecasts that, within the type category, multi chamber is expected to witness higher growth over the forecast period due to more drug compatibility and separation with multi chamber bags.
• Within the application category, hospital is expected to witness higher growth over the forecast period due to growing number of intravenous therapies delivered in hospital settings.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more hospital construction and increase in intravenous therapies.

Emerging Trends in EVA Infusion Bag Market

In the years 2025 to 2027, the eva infusion bag market will transition from commodity fluid containers to customized systems for different market applications. Based on Lucintel's analysis, the transition will be due to the integration of single-use systems, increasingly stringent control of extractables, and a desire to improve the sustainability of packaging systems. Additionally, there will be a preference to manufacture packaging systems near the location of final consumption.

• Sustainability: Starting from 2025, the EU packaging directives will require manufacturers of packaging materials to further reduce the volume of materials used in packaging and increase the recovery and recyclability of packaging. This directive will create a preference to use EVA films and other packaging materials in Healthcare Packaging to contain pharmaceuticals.
• Single Use Bioprocessing: The biopharmaceutical industry will further increase the use of EVA bags in single use bioprocessing systems. Concern for product contamination during processing will create a preference for single-use bioprocessing systems, even if the systems are disposable.
• Functional Customization: In the same period, suppliers will provide EVA bags with additional barrier layers to protect the contained contents from the effects of combination with other pharmaceuticals or from the adverse effects of change in temperature.
• Automation and Traceability: Automated procedures for labeling, filling and inspecting are moving from large manufacturing facilities to smaller ones, and by 2025 the entire pharmaceutical industry is anticipated to digitize quality programs. Enhancements in automation and traceability will not only help pharmaceutical companies identify and reduce release errors, but also help them generate documentation required by hospitals for the "chain of custody" of pharmaceuticals.
• Regulatory Supply Diversification: By 2025, the pharmaceutical industry will have added multiple supply sources for medical devices in both North America and Europe, in addition to existing sources in Asia. The focus on supply risk and regulatory flexibility at the board level will ensure continued multiple supply source strategies.

Continued emphasis will be placed on raw material suppliers to consistently meet performance requirements while also improving environmental impacts. The biopharmaceutical segment of the industry will be willing to pay for certain enhancements. Supply partners that can integrate multiple supply and service offerings will be favored by risk-averse procurement departments.

Recent Developments in the EVA Infusion Bag Market

The market for EVA infusion bags will grow through 2027, especially as hospitals and pharmaceutical companies respond to changing regulatory constraints, and as hospitals shift from using PVC. With increasing demand for single-use systems, Lucintel expects the market will shift to single-use systems.

• Flexible EVA Infusion Bags: With the expansion of Fresenius Kabi's IV solution capacity in the U.S. in June 2025, the U.S. will have more local production of flexible EVA infusion bags. In the next 3 to 5 years, the U.S. will produce flexible EVA infusion bags and reduce the country's reliance on flexible EVA infusion bags from other countries.
• Single-use Systems: Material suppliers and bag manufacturers will work with biopharmaceutical companies to develop single-use systems, including the 2025 collaboration to create a single-use bioreactor of 2,000 liters (March 2025).
• New Developments: The first commercial use of a multi-layer EVA structure to provide a stereo-barrier for oxygen, and other gases, was announced for 500 ml. infusion bags (September 2025). The improved oxygen barrier will allow the use of EVA bags for infusion of more labile drugs.
• Regulatory Approval: The FDA is accelerating its review of container closure systems. A broader review of the extractables of components in contact with drugs is anticipated. Our competition was required to provide validation in 2026 for the first time. A supply mate received approval to provide us a 1,000 mL EVA bag in February 2026. This approval would provide better documentation and facilitate our purchasing decisions.
• Sustainability: There are ongoing assessments to reduce the use of materials in single use systems. One such assessment was to reduce the weight of a bag by 15% (November 2025). We expect that environmental friendliness will become an more important consideration in contracting. Other considerations, including cost, will also influence contracting decisions.

Drug/device combination products and other products that require PVC to be Vocal compliant will use EVA. Continuous drug/device combination products will be the focus of the industry, and suppliers of EVA will have the same challenges as PVC suppliers. The ability to produce locally and have larger, more established operations will help vendors capture a more defined and larger permanent market.

Strategic Growth Opportunities in the EVA Infusion Bag Market

The eva infusion bag market is expected to expand from 2024 to 2026 with increased adoption by hospitals, closure of systems by manufacturers and reduction in the use of PVC by manufacturers. Meanwhile, drug shortages, outsourcing of pharmaceutical manufacturing and shift to home-based care increase the demand for infusion therapy. According to Lucintel, customer value lies in application-specific infusion therapy as opposed to generic infusion bags.

• Advanced Drug Delivery: The demand for infusion bags for biologics and oncology and other products which require special consideration like oxygen sensitivity is anticipated to increase. In the absence of such products, pharmacy and other healthcare providers are forced to use infusion bags for compounding and storage of such products which increase the demand for drug shortage, and in turn encourage the use of infusion bags for specialized drug formulations.
• Home Infusion: Special consideration infusion therapy products and services can be used for home health care. The Centers Medicare and Medicaid Services estimated that as of January 2025, there were 1.5 million beneficiaries using home health care services. The agencies which provide home health care products and services that reduce the complexity of infusion therapy will be used and purchased by pharmacies and other healthcare institutions.
• New Markets: Growing demand for IV therapies in India, S.E. Asia, Latin America, and other growth markets provides an opportunity to establish local production and distribution. India's pharma exports to 214 countries in April 2025, offers potential for infusion systems manufacturers to source flexible, compatible packages. The ability and timeframe to gain local acceptance for infusion systems will dictate market entry.
• New Materials: The EU's Packaging Directive and other similar legislation will drive the adoption of infusion systems based on the principles of sustainable development, materials efficiency, and longer term use of infusion systems. Additionally, Infusion systems manufacturers will be required to demonstrate materials efficiency and reduction in system complexity to help procurement personnel achieve environmental targets.
• New Technology: Quicker, more accurate, in-line, and process analyses will improve yield, process control and allow for greater flexibility in batch size. Customer requirements for 100% production traceability for critical and sterile components is driving supplier requirements for traceability. Digital records of process controls and quality will enable suppliers to accomplish shorter lead times and charge a premium.

Dependable, quick contract validation based on digital evidence of process controls for infusion systems will drive premium prices. Combining lower environmental impact with standard infusion systems will improve competitive positions. Overall, qualified companies should benefit from a gradual improvement in market position.

EVA Infusion Bag Market Drivers and Challenges

The infusion bag market is changing because of different trends, including the use of more advanced technology, the growing demand for healthcare services, and different rules and regulations. More effective methods for producing biological products, as well as new infusion therapies, are creating a larger market for infusion bags. At the same time, producing infusion bags and meeting various regulations and rules, and addressing environmental concerns, make this a more difficult market. It is important for companies in this market to make infusion products that are effective, safe, and low cost. According to Lucintel, these products will find the most use in the pharmaceutical market, but the clinical and nutritional markets will also see significant growth.

The factors responsible for driving this market include:

• Customer Interests: The growing need for infusion and injection therapies, particularly for nutrition and biologics, has created more demand for flexible and lightweight infusion bags. The global spending on healthcare was estimated to be over $7 trillion in 2025. With higher spending, more healthcare services are expected to be offered. More infusion services will be needed, especially because of increased chronic health conditions and more home-based healthcare services.
• Development in Multilayer Films and Seals: The development of multilayer films and seals has revolutionized the manufacturing process of EVA bags. In 2025, advancements in EVA bag technology, in combination with improvements in barrier and sterilization technologies, enabled the production of EVA bags with greater leak-resistance and drug compatibility.
• Focus on Safety: The concentration on the safety of patients and the requirement of traceability and the need for the packaging to be airtight have created opportunities for the qualified infusion bags. International Standards (ISO) continued to influence the Pharmaceutical Packaging Validation industry. In the next 3 to 5 years, it is expected that the barriers to entry in the industry will increase. Only the most prepared and qualified companies will operate in the industry.
• Bags and Ports: Improvements in the design of infusion bags has allowed for the production of infusion bags that are better suited for the transport of sensitive medications. Ports have also been redesigned to reduce the amount of air that is trapped in infusion bags. Innovations in the design of infusion bags allowed for the production of bags with a greater range of capacities. The lower limit of this capacity range was reduced to 50 ml. Innovations in the design of infusion bags, along with the growing needs in the areas of Oncology, critical care and other areas, will allow the market for infusion bags to experience growth.
• Manufacturing Efficiency: Automation, standardized processes, and local production help reduce labour and increase consistency in producing EVA bags. In April 2025, some packaging lines mechanically packaged 100 bags per minute. Over the next 3-5 years, continued automation in packaging would lower the costs of transportation, energy and raw materials. Suppliers would be able to charge lower prices and still maintain a sterile package.

The challenges facing this market include:

• Raw Material Price Volatility: The first is the price of raw materials. There is a direct relationship between the price of a barrel of oil and EVA resin. Other raw materials including additives, films and components also affect the price of packaging. In March 2025, one barrel of oil was over 60 dollars. The continued volatility of the price of oil would affect the packaging industry. This would result in the use of alternative raw materials, longer-term contracts and increased focus on package optimization.
• Stringent Compliance Requirements: The second problem is the regulations and testing required for packaging to be used for IV fluids. The requirements for packaging for IV fluids include being sterile, having a long shelf life and not affecting the body negatively. The requirements increase the time and cost for testing and regulatory approval. In the next 5 years, smaller companies would be even further disadvantaged.
• Disposal Pressure and Environmental Concerns: Because EVA bags are single-use, concerns have been raised about the environment, especially waste disposal and incineration, considering that they are made of plastic and are not easily recyclable. Each year, thousands of tons of different kinds of plastic, including EVA bags, are discarded in various ways by healthcare facilities throughout the world. The lack of a practical alternative will promote research into the development of designs that use other materials, or systems to ease the impact on the environment, during the whole life cycle of the product, including collection and recycling.

Due to demographic changes and advancements in medical technology and sciences, infusion therapies will become more commonplace, as will the use of medical products and services in the patient's domestic environment. Reusable systems and packaging will be developed to address the needs of the aforementioned markets. Though concerns will be raised regarding the safety and affordability of infusion systems and packaging, the environmental impact of infusion systems and packaging will be of primary concern.

List of EVA Infusion Bag Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies eva infusion bag market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eva infusion bag market companies profiled in this report include-

• Baxter International
• B. Braun
• Fresenius Kabi
• Weigao Group
• ICU Medical
• Metrix
• Technoflex
• Bexen Medical
• Eraser Medical
• Valmed

EVA Infusion Bag Market by Segment

The study includes a forecast for the global eva infusion bag market by type, application, and region.

EVA Infusion Bag Market by Type [Value ($M) from 2019 to 2035]:

• Single Chamber
• Multi Chamber

EVA Infusion Bag Market by Application [Value ($M) from 2019 to 2035]:

• Hospital
• Clinic
• Others

EVA Infusion Bag Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the EVA Infusion Bag Market

The eva infusion bag market has been shaped by localization of pharmaceutical supply chains, supply chain resiliency of hospitals and increasing requirements for sterile drug packaging. From 2025 to 2027, most companies will have prioritized and invested in validated polymer systems and manufacturing facilities in regions. According to Lucintel, this situation will create intense market competition in the health care industry.

• United States: In 2025, the administration implemented a 10% import tariff and Fresenius Kabi opened several pharmaceutical manufacturing facilities in the U.S. As such, U.S. based infusion bag manufacturers would have an advantage over U.S. based importers of resin, and domestic manufacturers of infusion bags over importers.
• China: In 2025, the China Food and Drug Administration approved 2,289 new medical devices. As such, local manufacturers of infusion systems and parenteral nutrition systems have been developed. Local manufacturers of infusion and parenteral systems, along with the local approval of medical devices, create an environment where Chinese manufacturers of infusion and parenteral systems would be adopted before imported systems.
• Germany: B. Braun's 2025 investment plan has been disclosed, outlining plans to enhance automated production and logistics at its Melsungen site. The company has been investing to expand its infusion therapy business. This is relevant because Melsungen has the potential to manufacture and consistently supply high-tech, automated EVA film to the pharmaceutical and other industries.
• India: The Indian government's strategies to localize the production of medical devices, especially through the combination of production-linked incentives and import substitution, are gaining traction. The pharmaceutical industry has benefited from similar policies. The 2025-26 Indian Union Budget allocated funds to further bolster the pharmaceutical sector. These policies have increased the local production of medical devices. Relevant: The local production of infusion bags in India has improved.
• Japan: Rising demand in pharmaceuticals has led Terumo to boost its 2025 fiscal investment to $672 million. This investment focuses on global manufacturing and R&D. Improving EVA bags has the potential to enhance safe and effective delivery systems for clinical care. Rising automation in the production of EVA bags will provide improving delivery systems for clinical care.

Features of the Global EVA Infusion Bag Market

• Market Size Estimates: eva infusion bag market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: eva infusion bag market size by type, application, and region in terms of value ($B).
• Regional Analysis: eva infusion bag market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the eva infusion bag market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eva infusion bag market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the eva infusion bag market by type (single chamber and multi chamber), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?